{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapy+Regimen&page=3", "query": { "intervention": "Chemotherapy Regimen", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 8177, "total_pages": 818, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapy+Regimen&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapy+Regimen&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-01T06:20:17.793Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02073487", "title": "Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "T-DM1", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Lapatinib", "type": "DRUG" }, { "name": "Abraxane", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 32, "start_date": "2014-02", "completion_date": "2019-01", "has_results": true, "last_update_posted_date": "2021-09-22", "last_synced_at": "2026-10-01T06:20:17.793Z", "location_count": 3, "location_summary": "Houston, Texas • Sugar Land, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Sugar Land", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02073487" }, { "nct_id": "NCT02779855", "title": "Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Ductal Carcinoma", "Invasive Breast Carcinoma", "Invasive Ductal Breast Carcinoma" ], "interventions": [ { "name": "Talimogene laherparepvec", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 50, "start_date": "2017-05-02", "completion_date": "2025-08-26", "has_results": true, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-10-01T06:20:17.793Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02779855" }, { "nct_id": "NCT03526835", "title": "A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced/Metastatic Solid Tumors", "Colorectal Cancer", "Gastric Cancer", "Gastroesophageal-junction Cancer", "NSCLC", "HNSCC", "Head and Neck Squamous Cell Carcinoma", "Esophageal Cancer" ], "interventions": [ { "name": "MCLA-158", "type": "DRUG" }, { "name": "MCLA-158 + Pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "MCLA-158 + FOLFIRI", "type": "COMBINATION_PRODUCT" }, { "name": "MCLA-158 + FOLFOX", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Merus B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 560, "start_date": "2018-05-02", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-01T06:20:17.793Z", "location_count": 31, "location_summary": "La Jolla, California • Los Angeles, California • San Diego, California + 25 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03526835" }, { "nct_id": "NCT04165798", "title": "KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Tumor Imaging", "type": "DIAGNOSTIC_TEST" }, { "name": "Tumor Tissue Collection", "type": "PROCEDURE" }, { "name": "Blood Sample Collection", "type": "PROCEDURE" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1065, "start_date": "2019-12-19", "completion_date": "2032-02-13", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-01T06:20:17.793Z", "location_count": 18, "location_summary": "Gilbert, Arizona • Duarte, California • San Francisco, California + 14 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04165798" }, { "nct_id": "NCT01604863", "title": "A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "HGS1036 + Paclitaxel + Carboplatin", "type": "DRUG" }, { "name": "HGS1036 + Cisplatin + Etoposide", "type": "DRUG" }, { "name": "HGS1036 + Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Human Genome Sciences Inc., a GSK Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2012-06", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2012-11-01", "last_synced_at": "2026-10-01T06:20:17.793Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Boston, Massachusetts", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01604863" }, { "nct_id": "NCT06625047", "title": "Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Astrocytoma, IDH-Mutant", "Glioblastoma", "Glioma", "Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted" ], "interventions": [ { "name": "Assessment", "type": "BEHAVIORAL" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Telemedicine Visit", "type": "OTHER" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "BEHAVIORAL", "OTHER", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-10-07", "completion_date": "2025-11-12", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-10-01T06:20:17.793Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06625047" }, { "nct_id": "NCT00005838", "title": "Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Adenocarcinoma of the Lung", "Adenosquamous Cell Lung Cancer", "Large Cell Lung Cancer", "Squamous Cell Lung Cancer", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Non-small Cell Lung Cancer" ], "interventions": [ { "name": "shark cartilage extract AE-941", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "vinorelbine tartrate", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 756, "start_date": "2000-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-23", "last_synced_at": "2026-10-01T06:20:17.793Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005838" }, { "nct_id": "NCT00005958", "title": "Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "Transitional Cell Cancer of the Renal Pelvis and Ureter" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-04", "last_synced_at": "2026-10-01T06:20:17.793Z", "location_count": 12, "location_summary": "La Jolla, California • Sacramento, California • Washington D.C., District of Columbia + 9 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Gurnee", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005958" }, { "nct_id": "NCT03450343", "title": "Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Large B-Cell Diffuse Lymphoma" ], "interventions": [ { "name": "Oral azacitidine", "type": "DRUG" }, { "name": "R-ICE", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2019-04-04", "completion_date": "2024-01-30", "has_results": false, "last_update_posted_date": "2024-10-28", "last_synced_at": "2026-10-01T06:20:17.793Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03450343" }, { "nct_id": "NCT01321008", "title": "Stage I/II Nasal NK Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Radiation", "type": "RADIATION" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2011-05", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2015-02-05", "last_synced_at": "2026-10-01T06:20:17.793Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01321008" } ] }